A link between infectious agents and atherosclerosis has been postulated for decades. This review describes the epidemiological and biological evidence linking cytomegalovirus and Chlamydia pneumoniae to atherosclerotic disease. Case-control studies and histologic evidence from atheromatous specimens support an association between atherosclerosis and infection with these two microorganisms, and small interventional trials appear to confirm the link with C. pneumoniae, but these findings require confirmation in larger studies. A lack of clinically relevant animal models has hampered investigations regarding biological mechanisms, particularly for C. pneumoniae.
These investigators initially reported an overall OR of 1.57 (95% CI, 1.03 -2.40), linking CMV seropositivity to atherosclerosis. However, after adjustment for other atherosclerosis risk factors, the OR fell to a nonsignificant 1.36 (95% CI, 0.81 -2.28) [9] . Thus, the strength of the association was quite modest, but specificity was suggested by the lack of an association for atherosclerosis and antibodies to herpes simplex virus type 1 or 2. In a subsequent report of the same data [10] , the OR, after adjustment for other atherosclerosis risk factors, demonstrated a dose response (OR: 1.0 for CMV titer of õ4, 1.5 [95% CI, 0.8 -2.9] for CMV titer of 4 -20, and 5.3 [95% CI, 1.5 -18.0] for CMV titer of §21). Subjects in the ARIC Study report had donated the blood that was tested for CMV antibodies in 1974 and were examined by ultrasonography in 1987 -1992, thus establishing that CMV seropositivity predated atherosclerotic disease (temporal correctness of association).
The most compelling epidemiological evidence for a role of CMV in atherosclerosis comes from restenosis data following coronary atherectomy. Zhou et al. [11] reported that 22 (43%) of 49 CMV-seropositive subjects developed restenosis (as measured by angiography repeated at 6 months), vs. only 2 (8%) of 26 CMV-seronegative subjects (OR, 9.00 [95% CI, 1.91 -42.38]; P Å .002). Furthermore, CMV seropositivity was a stronger predictor of restenosis than was diabetes (OR, 1.16; P Å 1.0), hypertension (OR, 1.96; P Å .18), smoking (OR, 0.57; P Å .34), male gender (OR, 2.44; P Å .19), or presence of unstable angina at the time of atherectomy (OR, 0.85; P Å .78). A dose-response relation linking increasing CMV antibody titer with increasing risk of restenosis was found, similar to ARIC Study data. No association was found with seropositivity for hepatitis A virus (i.e., specificity).
Doubt about CMV's role in atherosclerosis has been cast by CMV in atherosclerotic vs. nonatherosclerotic tissue, 1.4 [95% CI, 1.0 -1.9]) [8] . However, these studies have also revealed significant methodological differences (PCR vs. dot-blot or other detection methods), calling into question their overall sclerosis lesions in 17 of 18 studies (reviewed in [8] ), thus establishing excellent consistency of the association. Many of those validity. studies link CMV seropositivity to stenotic lesions of cardiac allografts (i.e., transplant vasculopathy). Transplant vasculopathy C. pneumoniae and Atherosclerosis has some similarities to typical atherosclerosis but also has several important differences, particularly in that it is concentric in In contrast to CMV, the link between C. pneumoniae and atherosclerosis was initiated and continuously strengthened by nature rather than producing the patchy lesions seen with native vessel disease. However, all five studies of atherosclerosis in epidemiological data, and the biological/mechanistic evidence is much weaker. In the late 1980s, researchers in Finland noted nontransplant recipients also found an association with CMV seropositivity, with an odds ratio (OR) of 1.3-3.2. One such an approximately twofold higher risk of IgG and/or IgA antibodies to C. pneumoniae in patients with myocardial infarction study linking CMV to prevalent atherosclerosis in a nontransplantation population was part of the Atherosclerosis in Commuor angina than in similar control subjects [12] . Since then, no less than 17 other studies have confirmed an association benities (ARIC) Study [9] . The ARIC Study examined carotid intimal medial thickness as measured by B-mode ultrasonography tween coronary events or prevalent atherosclerotic disease and seropositivity for C. pneumoniae, with ORs of 1.5 -10 (average (a well-established technique for identifying prevalent atherosclerotic disease in the carotid arteries).
OR, Ç2.5) (reviewed in [8] Thus, the consistency of the association is excellent, and the Biological plausibility is the weakest link for establishment of C. pneumoniae as a cause of atherosclerosis. Studies have strength is similar to that for other well-established atherosclerotic risk factors. Many of the studies used coronary events as been profoundly hindered by a lack of appropriate animal models [18] . One study utilizing rabbits that were inoculated intrathe measure of association, and thus it is not clear whether C. pneumoniae is linked to the atherosclerotic process itself or nasally with C. pneumoniae and fed a cholesterol-enhanced diet demonstrated accelerated atherosclerosis in these rabbits to plaque instability and consequent events. Potential shortcomings of these data center around the definition of seropositivity.
vs. its development in uninfected animals [19] . Furthermore, treatment of infected animals with azithromycin prevented this Many of the studies utilized different assays and levels of antibody to define a seropositive subject. In some studies, seroacceleration. However, chlamydial antigen was detected in only two of nine infected rabbits [19] . In vitro, chlamydial replicapositivity was even defined post-hoc. There may also be a significant bias against publishing negative data, thus slanting tion can be altered under the influence of specific cytokines to form an aberrant or persistent infection [13] . Until mechanistic the preponderance of evidence toward an association.
Further epidemiological evidence suggests that the associadata are more sound, the question as to whether C. pneumoniae is a cause of atherosclerosis or is an innocent bystander will tion of C. pneumoniae with atherosclerotic tissue is more specific than for CMV. Histologic or genetic analysis of atheroscleremain [20] . rotic tissue has been performed and in six of seven studies demonstrated C. pneumoniae in some atherosclerotic lesions Interventional Studies in Humans (reviewed in [13] ). Immunofluorescence staining of atherectomy specimens identified C. pneumoniae in up to 79% of Of all epidemiological data, randomized, blinded intervention trials provide the highest level of evidence of a causeatherosclerotic lesions, vs. only 4% of nonatherosclerotic tissue specimens [14] . C. pneumoniae has even been isolated from effect association. CMV infection may not need to proceed to lytic stages of replication to cause disease, on the basis of the arterial lesions of at least one patient with coronary disease [15] and another with cerebrovascular disease [16] . These data mechanistic data regarding IE-72 and IE-84. Thus, antiviral therapy may not prevent atherosclerotic lesions, and the most add to the strength and specificity of the association between C. pneumoniae and atherosclerosis.
effective therapies for CMV are intravenous preparations with marked toxicity and cost. No interventional trials with use of However, like seropositivity data, histologic and PCR data have been collected with nonstandardized methods. For examanti-CMV therapy have been performed among patients with atherosclerosis. In contrast, there are low-cost, well-tolerated ple, for the culture-positive patient described by Ramirez et al. [15] , only 1 of 2 laboratories performing immunostaining and oral therapies for C. pneumoniae infection, and two small preliminary studies have recently been reported [21, 22] . only 3 of 4 laboratories performing PCR found the arterial sample from that patient to be positive; of the 9 specimens in One of these studies, the ROXIS pilot study [21] , randomly assigned 212 men with recent evidence of coronary syndromes that study that were culture-negative, 6 were positive by either immunostaining or PCR. Furthermore, inhibitors of the PCR to receive roxithromycin, a macrolide with good activity against C. pneumoniae, or placebo. The major outcomes meaassay may be present in atheromatous material [13] . Thus, there may be significant false-positives and/or false-negatives when sured were severe, recurrent ischemia, acute myocardial infarction (MI), death, or combinations of these. The study found PCR or immunohistochemistry is utilized.
Temporal sequence of C. pneumoniae infection predating a significant difference between the groups when the combined endpoint of recurrent angina plus acute MI plus death was atherosclerosis (or at least a coronary event) is supported by the time delay of several weeks to generate antibody to assessed (nine events with placebo vs. one event with roxithromycin; P Å .04). However, there are many flaws in this study. C. pneumoniae after infection; thus, all studies of seropositivity support the theory that C. pneumoniae infection predates the C. pneumoniae antibody status was not determined prior to study enrollment, but was subsequently shown to be roughly clinical coronary event but not necessarily atherosclerosis itself. However, the ARIC Study investigators have provided eviequal in the placebo and roxithromycin groups (49% and 47%, respectively). There were many dropouts in both groups due dence of C. pneumoniae seropositivity predating prevalent atherosclerosis, as measured again by B-mode ultrasonography of to revascularization procedures (e.g., coronary artery bypass grafting [CABG] ), which the authors did not include as an the carotid arteries [17] . In that study, atherosclerosis was defined by a carotid artery intimal-medial thickness in the §90th endpoint. If CABG had been included as an endpoint, the number of events in the placebo group would have been 22, percentile, and C. pneumoniae seropositivity was defined by a serum antibody titer of §1:8. After adjustment for age, hypervs. 17 in the roxithromycin group. The second interventional study was methodologically more tension, diabetes mellitus, low-and high-density lipoprotein cholesterol levels, and educational level, the OR for C. pneusound [22] but also of limited size/power. In that study, C. pneumoniae -seropositive men with recent MI were randommoniae seropositivity for subjects with atherosclerosis was 2.0 / 9c64$$ap55 03-15-99 09:04:42 cida UC: CID
